Luigi Costa has more than 20 years of experience in the international pharmaceuticals and biotech industry. Previously, he held the position of vice president of Europe, Middle East and Africa for Onyx Pharmaceuticals, a global biopharmaceutical company based in San Francisco, California. Mr. Costa was responsible for the startup of the company’s international organisation and for the prelaunch and launch of its haematology drug, Kyprolis, in over fifty countries outside the USA. Prior to joining Onyx Pharmaceuticals, he spent eight years with Amgen holding leading management positions including head of International Oncology Franchise and general manager of Italy and France. He has also held various positions with Eli Lilly. He holds a BSc in Business Administration from the University of Parma and an MBA from SDA Bocconi in Milan. Mr. Costa is an Italian citizen, and resides in Switzerland.
Dr. Lisa Rojkjaer,MD, is a board-certified hematologist with more than 15 years of executive global and regional clinical development and medical affairs expertise within biotech and pharma industry, and has extensive experience in the development of both biologics and small molecules in haematology and immunology. She was formerly Global Clinical Program Head, Oncology Global Development with Novartis Pharmaceuticals, CMO at Molecular Partners and Vice President, Head of Clinical Development at Morphosys AG. Dr. Rojkjaer holds a medical degree from the University of Toronto, and is board certified in both internal medicine and hematology. She is a Canadian citizen and resides in Switzerland.
Marco G. Renoldi, MD, has served as Chief Business Officer since November 2014. Prior to joining Nordic Nanovector, Mr. Renoldi served as SVP & Chief Commercial Officer at Shionogi Ltd., from July 2012 to October 2014. From January 2009 to June 2012 he served as Executive Director & International Franchise Head, Oncology-Hematology at Amgen, where he had previously led the Italian affiliate as Managing Director. Prior to joining Amgen, Mr. Renoldi held national, regional and global R&D and business roles at Novartis, Searle-Monsanto and Pharmacia. In his 28-year industry experience Mr. Renoldi has developed product lines and businesses, including start-ups. Mr. Renoldi holds a medical degree from the University of Milan and an MBA from Fondazione IDI/Assolombarda. Mr. Renoldi is an Italian citizen and he resides in Switzerland.
Tone Kvåle has more than 20 years of experience from the biotech industry. She has been CFO in Nordic Nanovector since November 2012. Formerly CFO in NorDiag (public Company), Kavli Holding and Dynal Biotech, and she has held senior management positions at Invitrogen/Life Technologies/Thermofischer (US). Mrs. Kvåle has a diploma in Finance & Administration from Harstad University College (1990). Mrs. Kvåle is a Norwegian citizen, and resides in Norway.
Dr. Jostein Dahle, PhD, has more than 15 years of experience in cancer research. He has previously been CEO of Nordic Nanovector and leader of the Radioimmunotherapy group at Institute for Cancer Research at the Norwegian Radium Hospital. He holds a Ph.D. in radiation biology from University of Oslo (2000) and a M.Sc. in biophysics from Norwegian University for Science and Technology in Trondheim (1995). Dr. Dahle is one of the inventors of Betalutin™ and has published more than 45 papers in the field of cancer and biotechnology. Dr. Dahle is a Norwegian citizen, and resides in Norway.
Anniken Hagen has more than 25 years of experience from the pharmaceutical industry and extensive knowledge of radio-pharmacy. In her previous position, she was Head of QA at Oslo University Hospital (Norsk medisinsk syklotronsenter AS) and responsible for building facilities and QMS for GMP manufacturing of positron emission radiopharmaceuticals (PET). The organization achieved manufacturing licence under her management and she was QP for the manufacturing activities. Previously, Mrs. Hagen worked in Algeta ASA as QC manager and was also a part of the team compiling quality dossier for IND application. From a prior employer, Pronova Biomedical AS, she has experience with cell based drug delivery systems for, among others, anticancer therapeutics. Mrs. Hagen is a trained chemist and earned a Cand. Scient. in radiochemistry from the University of Oslo. Mrs. Hagen is a Norwegian citizen, and resides in Norway.
Rita Dege has over 15 years of experience from global organizations and international start-ups. Before joining Nordic Nanovector in 2015 she was head of human resources with an international environmental advisory firm. She further held senior positions within human resources, learning and development with the global maritime industry, management consulting and finance. She holds a Diploma in languages, business and finance from Euro Business and Language School, Germany. Mrs Dege is a German citizen, and resides in Norway.